Vascular malformations represent one of the largest and
most underserved segments. The current Atreatment options are
limited. The market size of vascular malformations is expected to
increase during the forecast period (2024–2034) with the increasing
prevalence, disease awareness, and entry of promising emerging
treatment options.
LAS VEGAS, June 26, 2024 /PRNewswire/ -- DelveInsight's
Vascular Malformations Market Insights report includes
a comprehensive understanding of current treatment practices,
vascular malformations emerging drugs, market share of individual
therapies, and current and forecasted market size from 2020 to
2034, segmented into 7MM [the United
States, the EU4 (Germany,
France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Vascular Malformations Market
Report
- According to DelveInsight's analysis, the market size for
vascular malformations is expected to grow significantly by
2034.
- As per DelveIsight assessment, 70.5% of Vascular
Malformations cases are found in the 25–44 age group, while 40%
and 51% of diabetes cases are found in 25–44 and 45–60 aged
individuals, respectively.
- Leading vascular malformations companies such as ARTham
Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech,
Inc., Vascular Therapies, Inc., Palvella Therapeutics, Inc.,
Vaderis Therapeutics AG, and others are developing novel
vascular malformations drugs that can be available in the vascular
malformations market in the coming years.
- The promising vascular malformations therapies in the pipeline
include ART-001, NRL-1049, TARA-002, REC-994, Cobimetinib,
Sirolimus, QTORIN, VAD044, and others.
Discover which therapies are expected to grab the major vascular
malformations market share @ Vascular Malformations Market
Report
Vascular Malformations Overview
Vascular malformations refer to abnormalities in blood vessels
that develop during embryonic or fetal development. These
malformations can occur anywhere in the body and are typically
present from birth, although they might not become apparent until
later in life. They are generally categorized based on the type of
blood vessel affected (arteries, veins, capillaries) and their
appearance under imaging.
The causes of vascular malformations are often not fully
understood. They are thought to arise due to errors in the
development of blood vessels during fetal growth. Genetic mutations
and certain genetic syndromes can also predispose individuals to
these conditions. Unlike vascular tumors, which involve abnormal
growth of blood vessels, malformations are structural abnormalities
present from the outset.
Symptoms of vascular malformations can vary widely depending on
their location and size. Some common symptoms include pain,
swelling, discoloration of the skin, and in some cases, functional
impairment of the affected area. For example, a malformation in the
brain might lead to neurological symptoms, while one in the limbs
could cause swelling and pain.
Diagnosis typically involves a combination of imaging studies
such as ultrasound, MRI (Magnetic Resonance Imaging), or CT
(Computed Tomography) scans. These imaging techniques help
determine the location, size, and type of malformation present.
Additionally, angiography—a procedure that involves injecting
contrast dye into blood vessels and taking X-ray images—can provide
detailed information about the blood flow within the
malformation.
Vascular Malformations Epidemiology Segmentation
The vascular malformations epidemiology section provides
insights into the historical and current vascular malformations
patient pool and forecasted trends for the 7MM. It helps recognize
the causes of current and forecasted patient trends by exploring
numerous studies and views of key opinion leaders.
The vascular malformations market report proffers
epidemiological analysis for the study period 2020–2034 in the 7MM
segmented into:
- Total Prevalent Cases of Vascular Malformations
- Diagnosed Prevalent Cases of Vascular Malformations
- Type-specific Cases of Vascular Malformations
- Mutation-specific Cases of Vascular Malformations
- Treated Cases of Vascular Malformations
Vascular Malformations Treatment Market
The treatment of vascular malformations varies based on factors
such as the specific blood vessel affected, the type of
malformation or syndrome present, and the overall health of the
patient. While many vascular malformations cannot be cured
outright, treatment focuses on reducing symptoms. Capillary
malformations, which are typically flat, violet, or red patches on
the face, often respond well to laser therapy. In contrast, other
types of vascular malformations may require interventional
techniques such as transarterial, transvenous, or direct access
methods. For instance, venous malformations may be treated by
injecting a sclerosing medication directly into the affected area
to induce clotting. Effective management often involves combining
these approaches to address the lesion comprehensively.
The most frequently employed methods for addressing vascular
malformations include embolization, laser therapy, sclerotherapy,
and surgical intervention. Embolization is a less invasive
technique that closes abnormal blood vessels internally using
substances like adhesives or particles. In certain cases, surgical
excision of the malformation or treatment with radiosurgery (a form
of radiation) may be preferred.
Laser therapy is effective for treating superficial venous
malformations or the surface layer of deeper lesions. It targets
bluish discoloration of tissues such as the lips, mouth lining, and
skin. A cooling device is often used alongside lasers to protect
intact skin during treatment. Additionally, a combined approach of
laser therapy, surgery, and sclerotherapy is utilized for
effectively managing complex venous malformations.
To know more about vascular malformations treatment guidelines,
visit @ Vascular Malformations Management
Vascular Malformations Pipeline Therapies and Key
Companies
Some of the emerging therapies include ART-001 (ARTham
Therapeutics), NRL-1049 (Neurelis), TARA-002 (Protara
Therapeutics), REC-994 (Recursion), and others.
ART-001, an orally available PI3Kα inhibitor currently
under development for slow-flow vascular malformations, potently
and selectively inhibited PI3Kα. It demonstrated "antitumor" and
"anti-angiogenesis" effects in both in vitro and in vivo
preclinical models. In December 2022,
ARTham Therapeutics presented Phase II trial data at the
International Conference on Vascular Anomalies (VAC2023) in
Brussels, Belgium. The abstract
was selected for oral presentation on February 1st, 2023. This multicenter,
double-blind, randomized controlled study evaluated the efficacy,
safety, and pharmacokinetics of ART-001 in pediatric (≥ 2 years
old) and adult patients with slow-flow vascular malformations,
including venous malformation, lymphatic malformation
(lymphangioma), and Klippel-Trenaunay syndrome.
In January 2023, Neurelis
filed an Investigational New Drug (IND) application to the FDA for
NRL-1049, an investigational Phase I stage small molecule Rho
kinase (ROCK) inhibitor designed to potentially reduce the
accumulation of new lesions and alleviate neurological symptoms
associated with cerebral cavernous malformations (CCM), a disease
characterized by abnormally enlarged capillary cavities in the
brain and spinal cord.
Apart from these the other therapies in the pipeline for
vascular malformations treatment include
- Cobimetinib: Genentech, Inc.
- Sirolimus: Vascular Therapies, Inc.
- QTORIN: Palvella Therapeutics, Inc.
- VAD044: Vaderis Therapeutics AG
The anticipated launch of these emerging therapies for vascular
malformations are poised to transform the market landscape in the
coming years. As these cutting-edge therapies continue to mature
and gain regulatory approval, they are expected to reshape the
vascular malformations market landscape, offering new standards of
care and unlocking opportunities for medical innovation and
economic growth.
Discover more about Vascular Malformations drugs in
development @ Vascular Malformations Clinical
Trials
Vascular Malformations Market Dynamics
The dynamics of the vascular malformations market are expected
to change in the coming years. Increased public awareness,
improved access to health services, and understanding of
disease are identified in screening and diagnosis, thereby
acting as market drivers. Despite fewer companies involved in the
clinical development of lymphatic malformations, those few have
shown promising results. Currently, the pipeline for
vascular malformations includes drugs in the mid and early
phases of development, presenting a significant opportunity for
innovative and effective therapies. VIJOICE is currently the
only FDA-approved treatment for PROS, leaving the market for other
types of vascular malformations untapped.
Furthermore, potential therapies are being investigated for the
treatment of vascular malformations, and it is safe to predict that
the treatment space will significantly impact the vascular
malformations market during the forecast period. Moreover, the
anticipated introduction of emerging therapies with improved
efficacy and a further improvement in the diagnosis rate are
expected to drive the growth of the vascular
malformations market in the 7MM.
However several factors may impede the growth of the vascular
malformations market. The high rate of recurrence and poor
patient prognosis, coupled with the lack of an effective
strategy to cure vascular malformations in the market, means
that even after the approval of marketed products, they remain
under surveillance. Unanticipated negative outcomes in
real-world settings could lead regulatory bodies to withdraw their
permission for marketing. Venous malformations, which can be
challenging to diagnose and are frequently confused with
hemangiomas both in terminology and imaging, exacerbate this
issue.
Moreover, vascular malformations treatment poses a
significant economic burden and disrupts patients' overall
well-being and QOL. Furthermore, the vascular
malformations market growth may be offset by failures and
discontinuation of emerging therapies, unaffordable
pricing, market access and reimbursement issues, and a
shortage of healthcare specialists. In addition, the
undiagnosed, unreported cases and the unawareness about the
disease may also impact the vascular malformations market
growth.
Vascular
Malformations Market Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Key Vascular
Malformations Companies
|
ARTham Therapeutics,
Neurelis, Protara Therapeutics, Recursion, Genentech, Inc.,
Vascular Therapies, Inc., Palvella Therapeutics, Inc., Vaderis
Therapeutics AG, and
others
|
Key Pipeline Vascular Malformations Therapies
|
ART-001, NRL-1049,
TARA-002, REC-994, Cobimetinib, Sirolimus, QTORIN,
VAD044, and others
|
Scope of the Vascular Malformations Market
Report
- Therapeutic Assessment: Vascular
Malformations current marketed and emerging therapies
- Vascular Malformations Market
Dynamics: Key Market Forecast Assumptions of Emerging
Vascular Malformations Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Vascular
Malformations Market Access and Reimbursement
Download the report to understand which factors are driving
vascular malformations market trends @ Vascular
Malformations Market Trends
Table of Contents
1.
|
Vascular
Malformations Key
Insights
|
2.
|
Vascular
Malformations Report
Introduction
|
3.
|
Vascular Malformations
Overview at a Glance
|
4.
|
Vascular
Malformations Executive
Summary
|
5
|
Vascular
Malformations Key
Events
|
6
|
Epidemiology and Market
Forecast Methodology
|
6.
|
Disease Background and
Overview
|
7.
|
Vascular
Malformations Treatment and
Management
|
8.
|
Vascular Malformations
Guidelines
|
9.
|
Vascular
Malformations Epidemiology and
Patient Population
|
10.
|
Patient
Journey
|
11.
|
Key Endpoints in
Vascular Malformations
|
12.
|
Vascular Malformations
Marketed Drugs
|
13.
|
Vascular
Malformations Emerging
Drugs
|
14.
|
7MM Vascular Malformations Market Analysis
|
15.
|
Market Access and
Reimbursement
|
16.
|
KOL Views
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Vascular Malformations Epidemiology Forecast
Vascular Malformations Epidemiology Forecast –
2032 report delivers an in-depth understanding of the
disease, historical and forecasted epidemiology as well as the
vascular malformations epidemiology trends.
Vascular Malformations Pipeline
Vascular Malformations Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key vascular
malformations companies, including Nobelpharma, Venthera,
ONY Biotech, Vaderis Therapeutics, BridgeBio Pharma, Genentech,
Inc., among others.
Non-Hodgkin's Lymphoma Market
Non-Hodgkin's Lymphoma Market Insights, Epidemiology,
and Market Forecast – 2032 report deliver an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key NHL companies, including GAbbVie, Genmab,
Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics,
Jiangsu Hengrui Medicine, among others.
Non-Hodgkin's Lymphoma Pipeline
Non-Hodgkin's Lymphoma Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key NHL companies,
including Novartis, AstraZeneca, Genentech, BioInvent, Genmab,
SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva
Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune
Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.,
Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro
Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell
Therapy Ltd., Incyte Corporation, HUYA Bioscience International,
SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd.,
Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu
HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc.,
BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions,
Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi
Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2
Therapeutics, IGM Biosciences, Inc, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/vascular-malformations-market-to-grow-substantially-by-2034-assesses-delveinsight--key-companies---artham-therapeutics-neurelis-protara-therapeutics-recursion-genentech-vascular-therapies-palvella-therapeutics-302182699.html